Taken together, these results show that reduced DSG2 expression is an independent biomarker associated with a shorter biochemical recurrence in prostate cancer, thereby revealing the potential clinical utility of DSG2 as a prognostic biomarker of tumor aggressiveness for patients affected with this frequently occurring disease. Here, DSG2 is linked to neoplasm.